Affiliation:
1. Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD.
Abstract
As a nation, we remain vulnerable to threats posed by the intentional or unintentional use of chemical, biological, radiologic, and nuclear agents or emerging infectious diseases. Children represent an at-risk population and are particularly vulnerable to the effects of these agents because of their unique anatomical and physiologic features. Hence, it is imperative that their unique needs be considered and prioritized. In the current article, we highlight the status of medical countermeasure product development for children, with a specific emphasis on the neonatal population. The aim of this article is to discuss the evidence that has been used to support pediatric approval of medical countermeasure products by the US Food and Drug Administration under various regulatory pathways. Understanding the strengths and limitations of the data that support labeling of medical countermeasures for pediatric patients will help guide health care professionals providing care in the event of a chemical, biological, radiologic, and nuclear agent–related incident or emerging infectious disease outbreak.
Publisher
American Academy of Pediatrics (AAP)
Subject
Pediatrics, Perinatology, and Child Health
Reference36 articles.
1. Medical countermeasures for national security: a new government role in the pharmaceuticalization of society;Elbe;Soc Sci Med,2015
2. HHS Public Health Emergency Medical Countermeasures Enterprise implementation plan for chemical, biological, radiological and nuclear threats. Notice;Office of the Assistant Secretary for Preparedness and Response, Department of Health and Human Services;Fed Regist,2007
3. Building the strategic national stockpile through the NIAID Radiation Nuclear Countermeasures Program;Rios;Drug Dev Res,2014